Qualitative shift toward clinical testing and higher profitability
First written in FY2016. 21 of 32 entries say "Advanced", first in FY2017. Latest entry: 2026-11-13.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「For aS-Medium, the simplified culture medium for microbial detection launched two years ago, we began selling CC for detecting coliform bacteria, following AC for detecting general bacteria. The market for simplified culture media for microbial detection is expanding year by year, partly because of labor shortages in testing departments in the food industry and other sectors. We will continue developing and strengthening sales of products by application and microorganism type.」
For aS-Medium, the simplified culture medium for microbial detection, sales of CC for coliform bacteria began following AC for general bacteria, and development of and sales expansion for products by application and microorganism type were advanced. Sales in the sanitary inspection equipment business reached a record ¥1,928 million. - 2026-06-03AdvancedGeneral Meetings of Shareholders
「一昨年上市した簡易型微生物検出用培地『ａＳ－Ｍｅｄｉｕｍ』については、一般細菌群検出用の『ＡＣ』に続き、大腸菌群検出用の『ＣＣ』の販売を開始しました。」
aS-Mediumについて、一般細菌群向けに続き大腸菌群向け製品の販売開始まで進展した。 - FY2026-H1AdvancedAnnual report
「Through sales activities that accurately captured these demand conditions, together with steady optimization of selling prices, net sales for the interim consolidated accounting period reached a record high and have remained above the level planned for the current fiscal year. As a result, for the six months ended 30 September, net sales were ¥970 million, up 7.0% year on year, and operating profit was ¥125 million, up 180.4%.」
In the sanitary inspection equipment business, first-half sales reached a record high through sales activities and optimization of selling prices, while operating profit was ¥125 million, up 180.4% year on year. - FY2025AdvancedAnnual report
「As a result, net sales for the consolidated fiscal year were ¥1,840 million, up 0.4% year on year, and operating profit was ¥134 million, up 69.4%.」
The sanitary inspection equipment business achieved record-high sales since the company's founding, while operating profit also improved to ¥134 million, up 69.4% year on year. - FY2025-H1AdvancedAnnual report
「In connection with the launch of sales of the new simplified culture medium for microbial detection, aS-Medium, we are pursuing sales expansion activities, including shipping samples to a large number of customers.」
Following the launch of aS-Medium, the simplified culture medium for microbial detection, samples were shipped to a large number of customers and sales expansion activities began. Meanwhile, the sanitary inspection equipment business recorded net sales of ¥907 million and operating profit of ¥44 million, representing year-on-year declines in both sales and profit. - FY2024AdvancedAnnual report
「We began selling a new product, a simplified culture medium for microbial detection, aS-Medium. By making microbial testing easier for anyone to perform through the market launch of this product, we will contribute to further food safety.」
The sanitary inspection equipment business began selling the simplified culture medium for microbial detection, aS-Medium. Although business sales reached a record ¥1,834 million since the company's founding, operating profit was ¥79 million, roughly unchanged from the previous fiscal year. - FY2024-Q3AdvancedAnnual report
「We will continue working to secure earnings by promoting production rationalization, making appropriate investments in selling, general and administrative expenses, optimizing selling prices, and manufacturing and selling high-value-added products. As a result, for the nine months ended 31 December, net sales were ¥1,411 million, up 4.1% year on year, and operating profit was ¥88 million, up 22.8%.」
In the sanitary inspection equipment business, we advanced the production of and sales of high-value-added products, production rationalization, control of selling, general and administrative expenses, and optimization of selling prices, resulting in a 22.8% year-on-year increase in operating profit. - FY2024-Q2AdvancedAnnual report
「With the transition of COVID-19 to a Class 5 infectious disease and the recovery in inbound demand, demand for eating out has surpassed pre-pandemic levels. Sales by the main customers of this business, driven by demand for eating at home, delivery and takeaway, have also grown accordingly. Against this backdrop of stronger demand, sales of sanitary inspection equipment for bacterial testing remained strong. Orders for Petri dishes for N-NOSE, the cancer test developed for 株式会社ＨＩＲＯＴＳＵバイオサイエンス, also remained firm, and the dedicated production line began operating as planned. As a result, for the six months ended 30 September, net sales were ¥931 million, up 4.1% year on year, and operating profit was ¥73 million, up 53.8%.」
Sales in the sanitary inspection equipment business remained strong against a backdrop of growth in demand for eating out, eating at home, delivery and takeaway. The dedicated production line for N-NOSE Petri dishes also began operating as planned, and both net sales and operating profit exceeded the year-earlier levels. - FY2023SoftenedAnnual report
「As a result, net sales for the consolidated fiscal year were ¥1,761 million, up 4.9% year on year, and operating profit was ¥79 million, down 45.6%.」
The sanitary inspection equipment business recorded a 4.9% year-on-year increase in sales, while operating profit was ¥79 million, down 45.6%, indicating a weakening contribution from higher-margin operations. - FY2023-Q3SoftenedAnnual report
「On the cost side, prices for PS (polystyrene), the main raw material for Petri dishes, have eased slightly but remain elevated. In addition to continuing to actively pursue cost reductions through manufacturing rationalization, we continued working to raise selling prices. However, conditions did not allow us to absorb the corresponding deterioration in earnings, and profit remained weak, following the six-month consolidated accounting period. As a result, for the nine months ended 31 December, net sales were ¥1,355 million, up 6.0% year on year, and operating profit was ¥72 million, down 42.0%.」
Although net sales rose 6.0% year on year, the impact of persistently high PS prices could not be absorbed through rationalization and price increases, and operating profit fell 42.0% year on year. - FY2023-Q2SoftenedAnnual report
「On the cost side, prices for PS (polystyrene), the main raw material for Petri dishes, continued to rise. In addition to actively pursuing further cost reductions through manufacturing rationalization, we implemented selected increases in selling prices to customers. However, conditions did not allow us to absorb the corresponding deterioration in earnings, and profit remained weak, following the first-quarter consolidated accounting period. As a result, for the six months ended 30 September, net sales were ¥894 million, up 7.2% year on year, and operating profit was ¥48 million, down 32.5%.」
Although the sanitary inspection equipment business recorded higher sales, the impact of soaring PS prices could not be absorbed despite rationalization measures and selected price increases, and operating profit fell 32.5% year on year. - FY2023-Q1SoftenedAnnual report
「As recovery measures, the company actively implemented cost-reduction activities, including improved petri dish molding cycles, advances in IoT and rationalization through automation, but manufacturing costs deteriorated substantially. As a result, revenue for the three months ended the first quarter was ¥438 million, up 5.1% year on year, and operating profit was ¥27 million, down 42.2%.」
In the sanitary testing materials business, manufacturing costs deteriorated despite the implementation of cost-reduction measures for higher profitability. Revenue increased, while operating profit declined 42.2% year on year. - FY2022AdvancedAnnual report
「Revenue from culture media products was 111.9% of the previous fiscal year's level. For petri dish products, supported in part by increased demand for cancer-test petri dishes (N-NOSE) from HIROTSU Bio Science Co., Ltd., annual sales volume reached a record 82 million units, or 107.5% of the previous fiscal year's level.」
In the sanitary testing materials business, culture media revenue reached 111.9% of the previous fiscal year's level, while annual petri dish sales volume reached 82 million units, or 107.5%, expanding the business base for higher profitability, including clinical testing. - FY2022-Q3AdvancedAnnual report
「On the cost side, improvement in the cost ratio through increased production of petri dish and culture media products lifted gross profit to a record ¥676 million, with a gross margin of 52.9%. Manufacturing capabilities have continued to advance steadily.」
In the sanitary testing materials business, increased production of petri dish and culture media products improved the cost ratio, resulting in record gross profit of ¥676 million and a gross margin of 52.9%. - FY2022-Q2AdvancedAnnual report
「As the industrial structure of the food hygiene industry changed substantially during the COVID-19 pandemic, sales of commercial food products remained strong, and orders for cancer-test petri dishes (N-NOSE) from HIROTSU Bio Science Co., Ltd. remained firm. First-half revenue alone reached a record high since the company's founding. On the cost side, substantial improvement in the cost ratio through increased production of petri dish and culture media products resulted in gross profit of ¥434 million, a first-half record, with a gross margin of 52.0%.」
In the sanitary testing materials business, orders for cancer-test petri dishes for N-NOSE remained firm, and first-half revenue and gross profit alone reached record highs since the company's founding. - FY2022-Q1AdvancedAnnual report
「Temporary leave implemented in the previous fiscal year and the resulting optimization of reduced petri dish inventories improved the cost ratio. Quarterly gross profit alone reached a record ¥219 million, with a gross margin of 52.7%.」
In the sanitary testing materials business, including the clinical testing field, the company began receiving orders for petri dishes for the N-NOSE cancer test from HIROTSU Bio Science, and the quarterly gross margin alone reached a record 52.7%. - FY2021-Q2SoftenedAnnual report
「On the sales side, lower orders from the tourism industry and food-service market due to the impact of the novel coronavirus caused quarterly revenue alone to decline 8.3% year on year, while cumulative first-half revenue declined 7.9%.」
For the sanitary testing materials business's policy of higher profitability and growth, orders from the tourism industry and food-service market declined, resulting in an 8.3% quarterly revenue decline and a 7.9% decline for the cumulative first half. - FY2021-Q1SoftenedAnnual report
「For the time being, the company expects revenue to remain weak, down 5% to 10% from the same month of the previous year, and will proceed with the production adjustments and expense reductions described above.」
In the sanitary testing materials business, revenue for the foreseeable future is expected to decline 5% to 10% year on year. The policy of higher profitability and growth therefore includes production adjustments and expense reductions based on weak demand. - FY2020AdvancedAnnual report
「As a result, revenue for the current consolidated fiscal year was ¥1,570 million, up 2.4% from the previous fiscal year, and operating profit was ¥49 million, up 1.2%.」
Revenue in the sanitary testing materials business was ¥1,570 million and operating profit was ¥49 million, with both exceeding the previous fiscal year. - FY2020-Q3AdvancedAnnual report
「On the cost side, in addition to strong sales of high-margin culture media products, production transformation activities in the petri dish manufacturing division resulted in gross profit of ¥590 million, an increase of ¥50 million, or 9.3% year on year. As a result, revenue for the nine months ended the third quarter was ¥1,206 million, up 2.3% year on year, and operating profit was ¥43 million, down 12.2%.」
Gross profit improved by 9.3% year on year, while operating profit declined 12.2% year on year because of the impact of selling, general and administrative expenses and other factors. - FY2020-Q2Gross profit improves, operating profit declinesAnnual report
「On the cost side, gross profit also improved substantially to ¥394 million, up 9.3% year on year. As a result, revenue for the six months ended the second quarter was ¥800 million, up 3.9% year on year, and operating profit was ¥33 million, down 11.0%.」
In the sanitary testing materials business, gross profit improved to ¥394 million, up 9.3% year on year, while operating profit declined 11.0% year on year. - FY2020-Q1AdvancedAnnual report
「On the cost side, cost-reduction activities in the petri dish manufacturing division produced results, and the inventory reduction implemented in the previous fiscal year was completed. Gross profit recovered to ¥195 million, up 5.0% year on year, with a gross margin of 49.9%.」
Cost-reduction activities in the petri dish manufacturing division and completion of inventory reductions restored the gross margin to 49.9%, demonstrating progress toward higher profitability. - FY2019Continued operating profit declineAnnual report
「As a result, revenue for the current consolidated fiscal year was ¥1,533 million, up 0.4% from the previous fiscal year, and operating profit was ¥49 million, down 36.7%.」
In the sanitary testing materials business, revenue was largely maintained, while operating profit was ¥49 million, down 36.7% from the previous fiscal year. - FY2019-Q2RestatedAnnual report
「Meanwhile, the newly established Sales Strategy Planning Department and IT Systems Department are working together to launch new activities based on three approaches: retaining stable, ongoing customers and preventing lost orders; reactivating customers whose orders had lapsed; and acquiring new customers. The functions and roles of the sales planning team and telemarketing staff have been subdivided. Sales in the affected areas fell sharply because of the typhoon in Kansai and the Hokkaido earthquake in September, resulting in lower revenue than the previous year, but the measures described above are producing definite results. Sales in those areas recovered to typical levels in October.」
The company continues to overhaul its sales structure for sustainable growth in a mature market and reported that its measures are producing results. Meanwhile, quarterly revenue fell below the previous year's level because of the typhoon and earthquake. - FY2019-Q1AdvancedAnnual report
「As a result, revenue for the three months ended the first quarter was ¥393 million, up 0.9% year on year, and operating profit was ¥21 million, up 47.3%.」
In the sanitary testing materials business, revenue increased slightly while operating profit rose 47.3% year on year, demonstrating progress toward higher profitability. - FY2018-Q2AdvancedAnnual report
「Gross margin for the quarter ended the second quarter alone reached a record 50.6%. The gross margin for culture media manufacturing also remained high at 54.7% for the quarter ended the second quarter alone.」
In the sanitary testing materials business, the quarterly gross margins reached record highs of 50.6% for petri dishes and 54.7% for culture media, demonstrating progress toward higher profitability. - FY2017AdvancedAnnual report
「During the current consolidated fiscal year, the company achieved record profit levels through production transformation activities in the culture media manufacturing process. It is also actively developing new petri dish models, new culture media products and other new products to improve customer convenience.」
The company achieved record profit levels in the culture media manufacturing process and is developing high-value-added products, including new petri dish models and new culture media products. - FY2016First statedAnnual report
「The company will achieve a qualitative shift toward an even more profitable business by strengthening its production and sales systems for product lines in the clinical testing field.」
The company has set out a shift toward a high-profitability business by strengthening production and sales systems in the clinical testing field.